Drug intelligence / Profile preview

Grippostad Day

Development stage
Unknown
Lead developer
STADA
Modality
Small Molecules
Administration
Oral
01

Overview

Grippostad Day is an oral combination medication developed by STADA Arzneimittel for the symptomatic relief of the common cold and influenza. The formulation consists of three small molecule active ingredients: paracetamol (300 mg), caffeine (25 mg), and phenylephrine hydrochloride (5 mg). Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin G/H synthase 1 and 2 (COX-1 and COX-2). Caffeine acts as an adenosine A1 and A2a receptor antagonist and a non-selective phosphodiesterase inhibitor, which potentiates the analgesic effects of paracetamol and helps counteract the fatigue associated with viral infections. Phenylephrine hydrochloride is a sympathomimetic decongestant that targets alpha-1 adrenergic receptors to reduce nasal mucosal swelling. The drug is specifically indicated for daytime use to alleviate fever, aches, pains, sore throat, and nasal congestion in adults and adolescents aged 12 years and older.

Brand names
Grippostad Day
Other names
paracetamol + caffeine + phenylephrine hydrochloride
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ADORA2A (Adenosine A₂A Receptor)PGHS-1 (Prostaglandin G/H Synthase 1)ADRA1A (α1A)ADORA1 (Adenosine receptor A1 subtype)PDE (Phosphodiesterase family)

Beyond the preview

Go deeper on Grippostad Day.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Grippostad Day.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call